SLNO - Soleno Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.7400
-0.0100 (-0.57%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.7500
Open1.7600
Bid1.60 x 1000
Ask1.80 x 2200
Day's Range1.6900 - 1.8000
52 Week Range1.4500 - 3.6000
Volume35,912
Avg. Volume77,252
Market Cap55.171M
Beta (3Y Monthly)0.09
PE Ratio (TTM)N/A
EPS (TTM)-1.02
Earnings DateMar 14, 2019 - Mar 18, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Soleno Therapeutics Announces $16.5 Million Private Placement

    Financing Led by Abingworth; Andrew Sinclair, Partner, to Join Soleno’s Board Funding to Support Ongoing Phase III Clinical Program (DESTINY PWS) for DCCR in Prader-Willi.

  • Simply Wall St.last month

    Is Soleno Therapeutics, Inc.’s (NASDAQ:SLNO) CEO Pay Justified?

    In 2014 Anish Bhatnagar was appointed CEO of Soleno Therapeutics, Inc. (NASDAQ:SLNO). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we'll Read More...

  • GlobeNewswire2 months ago

    Soleno Therapeutics Presents Clinical Fat Loss Data on DCCR at the Obesity Society Meeting 2018

    Soleno Therapeutics, Inc. (SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that clinical data from a Phase II study (PC025) of diazoxide choline controlled release (DCCR) investigating the effects of DCCR treatment on hyperphagia and fat loss in patients with Prader-Willi Syndrome (PWS) were delivered today in a poster presentation at the Obesity Society Meeting 2018, taking place this week in Nashville, TN. “While the hallmark characteristic of PWS is hyperphagia, PWS patients also experience ectopic accumulation of body fat, obesity and associated cardiometabolic complications, which is the leading cause of death of PWS patients,” said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno.

  • What Should You Know About Soleno Therapeutics Inc’s (NASDAQ:SLNO) Future?
    Simply Wall St.10 months ago

    What Should You Know About Soleno Therapeutics Inc’s (NASDAQ:SLNO) Future?

    The latest earnings update Soleno Therapeutics Inc’s (NASDAQ:SLNO) released in December 2017 suggested that losses became smaller relative to the prrior year’s level – great news for investors Below isRead More...

  • Does Soleno Therapeutics Inc’s (NASDAQ:SLNO) Past Performance Indicate A Weaker Future?
    Simply Wall St.10 months ago

    Does Soleno Therapeutics Inc’s (NASDAQ:SLNO) Past Performance Indicate A Weaker Future?

    When Soleno Therapeutics Inc (NASDAQ:SLNO) released its most recent earnings update (30 September 2017), I compared it against two factor: its historical earnings track record, and the performance of itsRead More...

  • Soleno Therapeutics Inc (NASDAQ:SLNO): Is Breakeven Near?
    Simply Wall St.10 months ago

    Soleno Therapeutics Inc (NASDAQ:SLNO): Is Breakeven Near?

    Soleno Therapeutics Inc’s (NASDAQ:SLNO): Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. With the latest financial year loss of -US$10.39MRead More...